Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 1.05 -7.08% -0.08
XBIO closed down 7.08 percent on Friday, November 15, 2019, on 54 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical XBIO trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Inside Day Range Contraction -7.08%
BB Squeeze Ended Range Expansion -7.08%
Wide Bands Range Expansion -7.08%

Older signals for XBIO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Dialysis Chronic Kidney Disease Anemia Drug Therapies Refractory Acute Myeloid Leukemia Product Candidates Growth Factors
Is XBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 42.84
52 Week Low 0.99
Average Volume 686,149
200-Day Moving Average 10.3698
50-Day Moving Average 1.3102
20-Day Moving Average 1.2953
10-Day Moving Average 1.241
Average True Range 0.1548
ADX 24.91
+DI 20.9587
-DI 23.3786
Chandelier Exit (Long, 3 ATRs ) 1.2356
Chandelier Exit (Short, 3 ATRs ) 1.4637
Upper Bollinger Band 1.5593
Lower Bollinger Band 1.0313
Percent B (%b) 0.04
BandWidth 40.762758
MACD Line -0.0601
MACD Signal Line -0.0453
MACD Histogram -0.0148
Fundamentals Value
Market Cap 9.16 Million
Num Shares 8.72 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -0.72
Price-to-Sales 6.14
Price-to-Book 1.60
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.23
Resistance 3 (R3) 1.23 1.18 1.20
Resistance 2 (R2) 1.18 1.13 1.18 1.19
Resistance 1 (R1) 1.11 1.10 1.09 1.11 1.18
Pivot Point 1.06 1.06 1.04 1.05 1.06
Support 1 (S1) 0.99 1.01 0.96 0.99 0.92
Support 2 (S2) 0.94 0.98 0.93 0.91
Support 3 (S3) 0.87 0.94 0.90
Support 4 (S4) 0.87